

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 9/74, A61K 38/48</b>	<b>A1</b>	(11) International Publication Number: <b>WO 96/26269</b>
		(43) International Publication Date: 29 August 1996 (29.08.96)

(21) International Application Number: PCT/GB96/00423

(22) International Filing Date: 23 February 1996 (23.02.96)

(30) Priority Data:  
9503750.3 24 February 1995 (24.02.95) GB

(71) Applicant (for all designated States except US): COMMON SERVICES AGENCY [GB/GB]; Trinity Park House, South Trinity Road, Edinburgh EH5 3SE (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MACGREGOR, Ian, Randle [GB/GB]; 5 Buckstone Loan, Edinburgh EH10 6UD (GB). HARDY, John, Charles [GB/GB]; 17 Greenhill Place, Edinburgh EH10 4BR (GB). DRUMMOND, Olive [GB/GB]; 15 Main Street, Aberdour, Fife KY3 0UE (GB).

(74) Agents: McCALLUM, William, Potter et al.; Cruikshank &amp; Fairweather, 19 Royal Exchange Square, Glasgow G1 3AE (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

**Published***With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: THROMBIN PREPARATION

## (57) Abstract

A process for preparing thrombin which comprises treating a mixture comprising prothrombin, Factor Xa, Factor Va and phospholipids with calcium ions, at a pH less than pH 7.0 is provided. In particular the pH of less than pH 7.0 may be generated by the addition of the calcium ions or by buffering the preparation to less than pH 7.0. Thrombin preparations so produced may be subjected to further purification and are particularly stable even when substantially free of exogenous stabilising agents such as proteins, sugars, polyol and mixtures thereof, and may be subjected to freeze-drying and a virus inactivation by heat-treatment.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## THROMBIN PREPARATION

### Field of the Invention

The present invention relates to a novel process for the production of thrombin particularly human thrombin and to thrombin preparations capable of being produced in a freeze dried form, which may be heat-treated in order to inactivate any viruses present.

### Background of the Invention

Thrombin is the product of the activation of prothrombin by Factor Xa in plasma. It is a potent broadly specific serine proteinase that converts fibrinogen to fibrin and promotes fibrin cross-linking by activating Factor XIII. Amongst a number of other observed biological activities, thrombin also controls several feedback loops in the clotting cascade and induces the platelet release reaction (1, 2)

Thrombin has been used as a topical haemostatic agent for many years. However, it is as a component of fibrin sealant (fibrin glue) that the clinical use of thrombin is likely to expand. Thrombin is used in fibrin sealant to convert fibrinogen to fibrin on a cut surface or within a graft and numerous surgical applications have been described in a wide range of surgical specialities (3, 4).

Bovine thrombin is currently used widely as a topical haemostatic agent or as a component of commercial fibrin sealant products. While such thrombin products

are biologically effective, they are associated with well-documented risk of allergic responses and induction of antibodies to the bovine thrombin or to impurities such as bovine factor V, usually after repeat use (5, 6 and 7). Ortel et al (8) recently concluded that such acquired coagulation factor inhibitors probably occur more commonly than is currently appreciated and although frequently clinically benign, these inhibitors may be associated with life-threatening haemorrhage. For this reason the development of a process to produce human thrombin suitable for use as a topical haemostat or for inclusion in a fibrin sealant product, has been sought.

Intrinsically, thrombin is formed when prothrombin (Factor II) is converted by activated Factor X, activated Factor V, phospholipid and calcium ions into thrombin. Conversion of prothrombin to thrombin can occur without some of the associated components, however, the rate of conversion is undesirably slow.

There are three main in vitro prothrombin conversion methods known in the art. The first method relies on the use of thromboplastin. Prothrombin is converted to thrombin using thromboplastin preferably in the presence of calcium chloride. This is described in a number of patent specifications such as EP 0439156A and EP 0505604A. A disadvantage of this method is that the thromboplastin is usually a crude preparation which has been prepared from freshly homogenised brain, lung or intestinal tissue. This procedure is not appropriate for

the preparation of human thrombin as the reagents, depending on their source, can carry the risk of virus or cross-species contamination.

A second method utilises some components of snake venom to yield thrombin (9, 10, 11). However, it has been reported that some of the venoms do not cleave the same bonds within prothrombin, as the natural activator, Factor Xa (12). Thus, there may be dangerous implications should a non-physiological form of thrombin be used clinically.

The third in vitro method is essentially the same as the intrinsic in vivo process, wherein prothrombin is converted to thrombin by activated Factor X, Factor V, phospholipid and calcium ions under near physiological conditions. This has been described, for instance in, EP 0528701, EP 0378798 and US 5,219,995. However, the thrombin produced is often unstable unless exogenous proteins, polyols and/or sugars are added to the thrombin to stabilise it.

Since human thrombin is derived from plasma obtained from blood donations, there is a risk of contamination of the thrombin by any viruses present in the original blood donation. Thus, any human thrombin preparation designed for clinical use, should be subjected to a virus inactivation step, prior to use.

Virus-inactivation by solvent-detergent treatment has been described previously (13). However, the thrombin preparation may need to be subjected to further

purification steps in order to remove the solvent-detergent. Other workers have described the use of virus/inactivated prothrombin feedstocks, but have not described methods for virus/inactivation of the thrombin products prepared from them, for example EP 0378798 and EP 0543178. Terminal (e.g. a final step of a process) viral-inactivation of the product is viewed as probably the safest and most effective method of virus/inactivation, as it minimises the chance of recontamination.

There is thus a requirement in the art to produce thrombin which is terminally virus/inactivated, especially by heat-treatment.

Generally speaking the present invention is based on the surprising discovery that prothrombin can be converted to thrombin in good yield, under acidic conditions and that these acidic conditions promote the stability of the thrombin generated.

#### Summary of the Invention

More specifically, a first aspect of the present invention provides a process for preparing thrombin which comprises treating a mixture comprising prothrombin, Factor Xa, Factor Va and phospholipids with calcium ions at a pH less than pH 7.0.

Generally, the mixture comprising prothrombin, Factor Xa, Factor Va and phospholipids may be obtained from a supernatant of a cryoprecipitate (which is formed

by freezing and thawing plasma) of human plasma. The mixture may be obtained by chromatographic purification of the supernatant of cryoprecipitated plasma, generally by anion-exchange chromatography. More particularly a DEAE-cellulose eluate of absorbed supernatant of cryoprecipitated plasma, which may be used for the production of clinical Factor IX concentrates, can serve as the mixture for thrombin production (14). The mixture may comprise additional clotting factors, such as, Factor X, Factor V, Factor IX, Factor IXa and trace amounts of thrombin.

The prior art (e.g. EP 0378789 and EP 0528701) has previously taught the addition of low levels of calcium ions (5-25mM) to a mixture comprising prothrombin, at or around physiological conditions (pH 7.0-7.3) and EP 0528701 describes that the addition of higher levels of  $\text{CaCl}_2$  inhibits the preparation of thrombin. It might be expected that conversion of prothrombin to thrombin would proceed best in conditions which approach those of physiological conditions. It is thus a surprising feature of the present invention that thrombin may be prepared in particularly good yield at a pH of less than pH 7.0. Preferably the pH is between pH 6.0-7.0 and more preferably between pH 6.4-6.6. Without wishing to be restricted to any postulated theories, it is thought that the pH of less than pH 7.0 limits autodegradation of thrombin produced.

Generally the pH of less than pH 7.0 may be

generated by the addition of  $\text{Ca}^{2+}$  ions, (in particular  $\text{CaCl}_2$ ) at concentrations of 50mM-90mM, more preferably 60mM-80mM and most preferably 65mM-75mM, to the mixture.

Addition of  $\text{CaCl}_2$  in the ranges specified, further generally results in a drop in the pH of the mixture which may be sufficient to reach the required pH.

Alternatively, the mixture may be buffered to between pH 6.0-7.0 or more preferably between pH 6.4-6.6 by any suitable buffer known to buffer in the required range, before adding  $\text{Ca}^{2+}$  ions to initiate the conversion of prothrombin to thrombin. Examples of suitable buffers include MES (2-[N-Morpholino]ethanesulphonic acid); ACES (2-[2-Amino-2-oxoethyl]amino]ethanesulphonic acid); BES (N,N-bis[2-Hydroxyethyl]-2-aminoethanesulphonic acid); MOPS (3-[N-Morpholino]propanesulphonic acid); TES (N-tris[Hydroxymethyl]methyl-2-aminoethanesulphonic acid) and HEPES (N-[2-Hydroxyethyl]piperazine-N-[2-ethanesulphonic acid) and the like.

In order to convert substantially all the prothrombin to thrombin, the conversion should proceed for a period of time and at a suitable temperature to effect conversion. Typically the conversion should be allowed to proceed for 12-24 hours and more preferably for 16-20 hours. The conversion may proceed at room temperature, typically between 18-25°C and does not require incubation at higher temperatures.

Generally thrombin prepared in this manner has a thrombin clotting activity of between 4,000-9,000 U/ml



and a specific activity of between 250-700 U/mg. This is considerably higher than the activity of the thrombin prepared by the process described in EP 0528701 (clotting activity 700-1,000 U/ml and a specific activity of 20-40 U/mg).

Some unwanted insoluble material may be found in the thrombin preparation probably due to the generation of fibrin by the action of generated thrombin on any fibrinogen present as a contaminant in the original DEAE-cellulose eluate and of insoluble calcium phosphate. The unwanted insoluble material may be removed by centrifugation or by a filtering process. However, in some instances, the preparation is too viscous and so the thrombin preparation is preferably diluted to reduce the viscosity. A dilution of 1 volume of thrombin preparation with up to 3 volumes buffer, for example 3 volumes which can be any buffer suitable for use in the range of pH 6.0-7.0, is generally carried out. Typical buffers include 40mM sodium gluconate or 20mM MES, both at pH 6.5. The diluted preparation may then be centrifuged or filtered to remove any insoluble material. Alternatively 20mM citrate, pH 6.5 may be used as the diluting buffer. This may remove the need for centrifugation or filtering, possibly due to the solubilisation of insoluble calcium phosphate.

The diluted thrombin preparation is suitable for immediate further processing, or may be stored at -40°C for at least six months without substantial loss of

clotting activity. Alternatively, the diluted material may be formulated and freeze-dried as an intermediate purity preparation.

A specific activity of the thrombin preparation of between 250 U/mg to 700 U/mg is equivalent to a thrombin purity of between about 6%-17.5% based on a comparison to a specific activity of pure  $\alpha$ -thrombin of 4,000 U/mg. While this is sufficient in most clinical instances, it is possible to subject the thrombin preparation to further processing to yield a thrombin of higher purity.

Further processing may comprise chromatographic purification of thrombin with an optional solvent/detergent virus inactivation step prior to chromatographic purification. A suitable solvent/detergent virus/inactivation step has been previously described by Edwards et al (13).

Chromatographic purification is generally carried out by cation-exchange chromatography. Typical cation-exchange resins which may be employed include Mono-S (TRADEMARK), S-Sepharose FF (TRADEMARK) and S-Sepharose Big Beads (TRADEMARK) although other sulphonate gels or other cation-exchangers may be employed. The chromatography step serves to remove solvent and detergent, if a solvent/detergent virus inactivation step has been carried out and also serves to purify the thrombin preparation.

Typically the thrombin preparation is bound to the cation-exchange chromatography resin and a purified

thrombin is eluted using a suitable buffer with increased salt concentration. Examples of suitable buffers include 20mM citrate pH 6.5, 20mM MES pH 6.5 and 40mM gluconic acid pH 6.5. The pH of the buffer should preferably be in the range of pH 6.0-7.0 and more preferably pH 6.4-6.6 in order to preserve the activity of the purified thrombin. Usually several salts are suitable for eluting with any given cation-exchange resin and typically these include NaCl.

The concentration of eluted purified thrombin depends directly upon the amount bound to the resin, but typically concentrations of purified thrombin between 4,000-9,000 U/ml may be obtained. Even the lower range of these concentrations is adequate to allow suitable dilution with a formulation buffer, for subsequent freeze-drying.

Purified thrombin may be frozen directly in elution buffer and stored for up to six months without substantial loss of thrombin activity. However, for ease of storage it is desirable that the intermediate purity thrombin and purified thrombin, be freeze-dried.

Freeze-drying often results in a loss in activity of thrombin (intermediate purity thrombin and purified thrombin) and it is thus important to formulate the thrombin with a formulation buffer. This formulation buffer helps stabilise the thrombin during freeze-drying. Prior to formulating the thrombin, it is often desirable to centrifuge and/or filter the thrombin to remove

insoluble material.

The art has previously described that the addition of stabilising agents such as polyols, for instance, glycerol, mannitol and sorbitol; sugars such as sucrose and glucose and/or exogenous proteins such as albumin, to a thrombin preparation is desirable to improve the stability of a thrombin preparation, especially during freeze-drying. It is thus a surprising feature of the present invention that thrombin may be prepared, which is substantially stable without additional stabilising agents such as polyol, sugar, protein and mixtures thereof.

Thus, in a further aspect the present invention provides a thrombin preparation, the preparation comprising thrombin substantially free of exogenous stabilising agents (such as protein, sugar, polyol and mixtures thereof) buffered at a pH of less than pH 7.0.

Generally the thrombin preparation is freeze-dried and optionally heat-treated. Thus, in a still further aspect, the present invention provides a freeze-dried, optionally heat-treated, thrombin preparation, substantially free of exogenous stabilising agents, such as protein, sugar or polyol and mixtures thereof.

Preferably the thrombin preparation is buffered to between pH 6.0-7.0, more preferably pH 6.4-6.6. This may be achieved by for instance 40mM gluconic acid or 20mM MES buffer in the suitable pH range. Preferably, the thrombin preparation further comprises citrate at a

concentration of 10mM-30mM, typically sodium citrate. More preferably the preparation further comprises sodium chloride at a concentration of between 100-250mM for example 100-200mM. A thrombin preparation comprising citrate and sodium chloride is found to be most stable to freeze-drying and optional heat-treatment. That is, the thrombin preparation retains a greatest percentage of clotting activity after freeze-drying and optional heat-treating.

Freeze-drying is preferably carried out employing a two-stage freezing procedure. The frozen product is then primary dried at a shelf temperature of -20° to -30°C and then secondary dried at a shelf temperature of +15° to +30°C.

The freeze-dried thrombin preparation may then be heat-treated in order to inactivate any virus contaminants. Typically dry heat-treatment is carried out at temperatures of between 70°C to 100°C for up to 96 hours. A particularly preferred heat-treatment is approximately 80°C for around 72 hours.

#### Detailed Description of Preferred Embodiments

Embodiments of the present invention will now be described by way of Example, with reference to the attached Figures.

Examples SectionExample 1 - Preparation of a mixture comprising prothrombin, Factor Xa, Factor Va and phospholipid by DEAE-cellulose

450 litres of cryoprecipitate plasma was adjusted to pH  $6.9 \pm 0.05$  and diluted with 150 litres of pyrogen free  $H_2O$  to a final volume of 600 litres. 6kg of DEAE-cellulose gel (DE-52 Whatman) was then added to the plasma/water solution and the resulting suspension mixed continuously for one hour to bind the clotting factors to the gel. The gel was then collected by centrifugation and the supernatant discarded. The gel was then resuspended in 30mM citrate, 30mM phosphate pH 6.9 buffer and the resulting suspension was poured into a chromatography column. The column was then packed by washing with 21 litres of the same buffer. The clotting Factors were then eluted from the column with an elution buffer of 30mM citrate, 30mM phosphate, 200mM NaCl, pH 6.9. The eluate pool (3.1 litres) was then filtered (0.45 $\mu$ m pore size) into sterile bottles and frozen.

The eluate pool contains substantial amounts of prothrombin (Factor II) (at 80 $\mu$ M and about 25% of the total protein). It also includes factors IX and X, activated and non-activated (at about 5 $\mu$ M), coagulant-active phospholipid and sufficient trace amounts of Factors V and VIII to support the physiological conversion of prothrombin to thrombin via the intrinsic clotting pathway.

Example 2 - Preparation of intermediate purity thrombin

Frozen DEAE-cellulose eluate (prepared according to Example 1) was thawed at room temperature or in a 37°C water bath. (Typical values of the eluate were as follows: conductivity = 17mS; pH = 7.0; 30mM citrate; 30mM phosphate; 200mM sodium; 200mM chloride; 15 mg/ml total protein and prothrombin 60 U/ml)

1M CaCl<sub>2</sub> solution was then added dropwise to the thawed eluate, with stirring, at a ratio of 75ml CaCl<sub>2</sub> to 1,000ml eluate, at 20°C. This resulted in a final calcium concentration of 70mM and a drop in pH in the mixture to pH 6.4-6.6. The reaction was allowed to proceed with stirring overnight for 18 hours at 20°C, to convert the prothrombin to thrombin.

In 15 experiments, the thrombin clotting activity was 6,333 ± 1,146 U/ml (mean ± SD) and specific activity of 508 ± 110 U/mg (see Figure 1). SDS PAGE indicated that effectively all the prothrombin band was converted into bands co-migrating with thrombin, by the end of the activation period.

Thrombin clotting activity was measured by fibrinogen clotting time at room temperature with visual detection and duplicate samples. To 200μl of human fibrinogen solution at 5 mg/ml in 50mM tris-HCl 100mM NaCl pH 7.5 was added 100μl of standard (1-4 U/ml) or test solutions of thrombin diluted in 50mM tris-HCl, 100mM NaCl pH 7.5 supplemented with 100mM CaCl<sub>2</sub> and 0.1% w/v bovine serum albumin, whereupon time to subsequent

clot formation was recorded. A standard curve was constructed by plotting  $\log_{10}$  thrombin concentration (U/ml) against  $\log_{10}$  clotting time (sec) using bovine thrombin standardised against the human alpha-thrombin standard 89/588. Thrombin clotting activity of test samples was derived by extrapolation from the standard curve (15).

Example 3 - Effect of varying the pH of the reaction solution during activation

Following the procedure described in Example 1, resulted in a mixture with a pH of 7.0-7.2. This immediately decreased to pH 6.5 on addition of  $\text{CaCl}_2$  to 70mM. There was then a steady decrease in pH to 6.1-6.3 during the conversion period (18 hours). The fall in pH was a requirement for the successful generation of thrombin of high activity. This was demonstrated by comparative experiments, where the pH of the solution was adjusted to pH 7.0 or pH 7.5 immediately after the addition of  $\text{CaCl}_2$ . Here the final pH values at the end of



the reaction period were pH 6.7 and pH 7.1 respectively and a much lower amount of thrombin activity was generated (see Table 1).

TABLE 1			
Example	pH of the mixture, immediately after CaCl <sub>2</sub> addition (adjusted as necessary)	pH of the mixture at the end of the conversion period (18 hours)	Clotting activity (IU/ml)
1	6.5	6.1	5716
2	7.0	6.7	2012
3	7.5	7.1	1493

In a further experiment, the mixture was buffered (20mM MES) to pH 6.5 immediately after CaCl<sub>2</sub> addition. This resulted in an additional small increase in conversion to thrombin, but the increase in clotting activity was insignificant.

Example 4 - Effects of varying the length of time or temperature employed for conversion of prothrombin to thrombin

Studies were carried out to determine the optimum time course for the conversion of prothrombin to thrombin. A comparison of the amount of thrombin generated at 16 and 24 hours indicated that a plateau had been reached by 16 hours.

An investigation was also carried out to determine the effect of incubation at 37°C for one hour prior to subsequent room temperature incubation, in view of a report that this step was necessary to obtain useful yields with this type of feedstock (European Patent Application No. 92401889.8). It was found that while the initial rate of thrombin generation exceeded that obtained at room temperature, the final yield of thrombin was no better at 16 or 24 hours as compared to conversion at room temperature.

Example 5 - Effects of varying calcium ion concentration on thrombin production

The amount of thrombin generated at 24 hours with a range of added calcium ion concentrations (seven batches of DEAE-cellulose eluates) was determined (Figure 2). It was found that the addition of 70mM calcium consistently resulted in efficient conversion of prothrombin to thrombin.

Example 6 - Viral inactivation by solvent/detergent

Thrombin prepared according to Example 2 was mixed by stirring with 0.3% tri-(n-butyl) phosphate and a 1% solution of Tween 80 at a temperature of 20°-30°C for 6 to 24 hours. This was sufficient to inactivate any contaminating lipid-enveloped viruses. The solvent/detergent was removed by chromatography.

Example 7 - Chromatographic purification of intermediate purity thrombin

The chromatography step serves to remove solvent and detergent and to purify the intermediate purity thrombin. A 1.6cm diameter chromatography column was packed with 10ml of S-Sepharose FF (TRADEMARK) at a linear flow rate of 2.2cm/min (equivalent to 4.5ml/min) using 40mM gluconic acid, 20mM MES, or 20mM citrate all at pH 6.5. 100ml of solvent/detergent treated thrombin according to Example 6 or intermediate purity thrombin according to Example 2, following a 1 + 3 dilution in equilibrating buffer was filtered at 0.45 $\mu$ m and applied to the column at the same flow rate. The column was then washed with equilibrating buffer until the absorbency at 280nm returned to baseline and solvent or detergent were detectable only below acceptable low levels, in the column effluent (typically approximately 150ml). Thrombin was then eluted from the column by washing with equilibrating buffer containing 0.5M NaCl. Purified thrombin was obtained in about 25ml at a typical concentration of 4,000 U/ml and 2mg/ml protein.

The typical yield of purified thrombin after the chromatography step was 88 $\pm$  16%. This yield refers to a thrombin preparation which was not subjected to a solvent/detergent virus inactivation step as described in Example 6.

Example 8 - Formulation, freeze-drying and terminal dry heat treatment

Thrombin prepared according to Examples 2 or 6 was centrifuged at 3,000 rpm for 20 minutes at room temperature and then filtered through a Millpore pre-filter (AP25) followed by a Whatman 0.2 $\mu$ m filter (Polydisc AS). The filtered solution was then diluted in a formulation buffer (40mM gluconic acid or 20mM MES, 20mM trisodium citrate, 150mM NaCl, pH 6.5) to a thrombin activity of 600 U/ml and dispensed in 2 ml lots into glass vials for freeze-drying.

Freeze-drying was performed in a super-Modulyo (Edwards, Crawley) freeze-dryer with a freezing temperature setting of -45°C, followed by a primary drying temperature setting of -25°C and a secondary drying temperature setting of +20°C.

The vials were then heat-treated to inactivate any contaminating viruses, at 80°C for 72 hours.

Example 9 - Comparison of a stabilising effect on thrombin of various formulation buffers

Thrombin was formulated in a variety of formulation buffers, in order to determine the optimum formulation buffer for stabilising thrombin during freeze-drying and subsequent heat-treatment (virus-inactivation).

Intermediate purity thrombin prepared according to Example 2 and purified thrombin prepared according to Example 7, were diluted with various formulation buffers

(as described in Table 2) to a thrombin concentration of 600 U/ml. The thrombin preparation was then freeze-dried according to Example 8 and a quantity of the freeze-dried thrombin was also subjected to a heat-treatment of 80°C for 72 hours. Thrombin clotting activity was determined, as previously described, to determine the percentage clotting activity that remained after freeze-drying and subsequent heat-treatment. The results are shown in Table 2.

It can be seen from Table 2 that formulation buffers comprising 20mM tris-HCL buffer at pH 7.2 with or without 20mM trisodium citrate and/or 150mM sodium chloride, resulted in a recovery of thrombin clotting activity, after freeze-drying, of greater than 74%. However, large losses in activity were seen post-heat-treatment, particularly in the absence of trisodium citrate. The inclusion of sodium chloride in the formulation buffer gave rise to an intact plug of material, whereas without sodium chloride, the plug retracted and collapsed.

Protein (e.g. Human albumin) can also be included in the formulation at concentrations of 0.5g/l - 10g/l, to act as a bulking agent and improve plug structure and appearance.

When the formulation buffer was made acidic by using gluconic acid or MES buffered at pH 6.5, recovery of thrombin clotting activity after dry heat-treatment was substantially improved.

Long term stability was determined using the

gluconic acid buffer formulation (see Table 2). These studies were performed by storing several vials at 4°C and 37°C, after freeze-drying and heat treatment. No loss in thrombin clotting activity was observed over a six month period, when comparing the 37°C stored thrombin to the 4°C stored thrombin.

TABLE 2				
Recovery of clotting activity (%)				
Formulation buffer	Intermediate purity thrombin		High purity thrombin	
	Post-FD	Post-HT	Post-FD	Post-HT
20mM Tris-HCL pH 7.2	96	12	93	12
20mM Tris-HCL pH 7.2 + 20mM trisodium citrate	92	56	91	56
20mM Tris-HCL pH 7.2 + 150mM NaCl	87	10	74	4
20mM Tris-HCL pH 7.2 + 20mM trisodium citrate + 150mM NaCl	91	41	90	51
20mM gluconic acid +20mM trisodium citrate + 150mM NaCl pH 6.5	100	99	93	85
20mM MES+ 20mM trisodium citrate + 150mM NaCl pH 6.5	nd	97	nd	86

FD = Freeze-drying

HT = Heat-treatment of 80°C for 72 hours in  
vial

nd = not done

**REFERENCES**

1. Fenton, J. W. (1981). Thrombin specificity. Ann. N. Y. Acad. Sci. 370:468-495.
2. Suttie, J. W. and C. M. Jackson. (1977). Prothrombin structure activation and biosynthesis. Physiol. Rev. 57:1-65.
3. Brennan, M. (1991). Fibrin Glue. Blood Rev 5:240-244.
4. Gible, J. W. and P. M. Ness. (1990). Fibrin Glue - The Perfect Operative Sealant. Transfusion 30:741-747.
5. Banninger, H., T. Hardegger, A. Tobler, A. Barth, P. Schupbach, W. Reinhart, B. Lammle, and M. Furlan. (1993). Fibrin Glue in the Surgery - Frequent Development of Inhibitors of Bovine Thrombin and Human Factor-V. Br. J. Haematol. 85:528-532.
6. Berruyer, M., J. Amiral, P. Ffrench, J. Belleville, O. Bastien, J. Clerc, A. Kassir, S. Estanove, and M. Dechavanne. (1993). Immunization by Bovine Thrombin Used with Fibrin Glue During Cardiovascular Operations - Development of Thrombin and Factors-V Inhibitors. J. Thorac. Cardiovasc. Surg. 105:892-897.



7. Rothenberg, D. M. and J. N. Moy. (1993).  
Anaphylactic Reaction to Topical Bovine Thrombin.  
*Anesthesiology* 78:779-782.
8. Ortel, T. L., L. A. Charles, F. G. Keller, P. K.  
Marcom, H. N. Oldham, W. H. Kane, and B. G. Macik.  
(1994). Topical Thrombin and Acquired Coagulation Factor  
Inhibitors - Clinical Spectrum and Laboratory Diagnosis.  
*Am. J. Hematol.* 45:128-135.
9. Denson, K. W. E. (1969). Coagulant and  
anticoagulant action of snake venoms. *Toxicon* 7:5-11.
10. Ngai, P. K. and J. Y. Change. (1991). A Novel One-  
Step Purification of Human alpha-Thrombin After Direct  
Activation of Crude Prothrombin Enriched from Plasma.  
*Biochem. J.* 280:805-808.
11. Feldman, P. and L. Winkelman. (1991). Preparation  
of special plasma products. In *Blood Separation and  
Plasma Fractionation*. Wiley-Liss, Inc., 341-383.
12. Rosing, J. and G. Tans (1991). Inventory of  
exogenous prothrombin activators. *Thromb. Haemostats.*  
65:627-630.
13. Edwards, C. A., M. P. Piet, S. Chin, and B.  
Horowitz. (1987). Tri(n-butyl) phosphate/detergent  
treatment of licensed therapeutic and experimental blood

derivatives. Vox. Sang. 52:53-59.

14. Middleton, S. M., I. H. Bennett, and J. K. Smith.  
(1973). A therapeutic concentrate of coagulation factors  
II, IX and X from citrated, factor VIII-depleted plasma.  
Vox. Sang. 24:441-456.

15. Gaffney, P. J., A. B. Heath, and J. W. Fenton.  
(1992). A collaborative study to establish an  
international standard for alpha-thrombin. Thromb.  
Haemostats. 67:424-427.

CLAIMS

1. A process for preparing thrombin which comprises treating a mixture comprising prothrombin, Factor Xa, Factor Va and phospholipids with calcium ions at a pH less than pH 7.0.
2. A process for preparing thrombin according to claim 1 wherein the mixture is obtained from a supernatant of a cryoprecipitate of plasma.
3. A process for preparing thrombin according to claim 2 wherein the mixture is obtained by chromatographic purification of the supernatant of cryoprecipitated plasma.
4. A process for preparing thrombin according to any preceding claim wherein the pH is between pH 6.0 - 7.0.
5. A process for preparing thrombin according to any one of claims 1 to 3 wherein the pH is between pH 6.4 - 6.6.
6. A process for preparing thrombin according to any preceding claim wherein the concentration of calcium ions is in the range of 50mM - 90mM.
7. A process for preparing thrombin according to any of claims 1 to 5 wherein the concentration of calcium ions is in the range of 60mM - 80mM.

8. A process for preparing thrombin according to any of claims 1 to 5 wherein the concentration of calcium ions is in the range of 65mM - 75mM.
9. A process for preparing thrombin according to any of claims 6 to 8 wherein the concentration of calcium ions is such as to result in said pH less than 7.0.
10. A process for preparing thrombin according to any of claims 1 to 8 wherein the mixture is buffered to said pH, before adding calcium ions.
11. A process for preparing thrombin according to any preceding claim further comprising generating a diluted thrombin preparation by diluting 1 volume of thrombin preparation with up to 3 volumes buffer, wherein the buffer is suitable for use in the range of pH 6.0 - 7.0.
12. A process for preparing thrombin according to claim 11 wherein the buffer comprises substantially 20mM citrate, and has a pH 6.5.
13. A process for preparing thrombin according to either of claims 11 or 12 further comprising centrifugation and/or filtration of the diluted thrombin preparation to remove unwanted insoluble material.

14. A process for preparing thrombin according to any of claims 11 to 13 further comprising further processing to yield a thrombin of higher purity, wherein the further processing comprises chromatographic purification and wherein the thrombin of higher purity is eluted using a suitable buffer in the range of pH 6.0 - 7.0.
15. A process for preparing thrombin according to claim 14 further comprising a solvent/detergent viral inactivation step, prior to the chromatographic purification.
16. A process for preparing a freeze-dried thrombin comprising preparing thrombin according to any of claims 12 to 15 and freeze-drying said thrombin.
17. A process for preparing a freeze-dried thrombin according to claim 15 further comprising heat-treating the freeze-dried thrombin in order to inactivate any viral contaminants.
18. A process for preparing thrombin according to any preceding claim wherein the thrombin is human thrombin.
19. A thrombin preparation, the preparation comprising thrombin substantially free of exogenous stabilising agents, such as protein, sugar, polyol and mixtures thereof, buffered at a pH of less than pH 7.0.


20. A thrombin preparation according to claim 19 buffered to between pH 6.0 - 7.0.
21. A thrombin preparation according to claim 19 buffered to between pH 6.4 - 6.6.
22. A freeze-dried thrombin preparation, the preparation comprising thrombin substantially free of exogenous stabilising agents, such as protein, sugar or polyol and mixtures thereof.
23. A freeze-dried thrombin preparation according to claim 22 further comprising 10mM - 30mM citrate.
24. A freeze-dried thrombin preparation according to claim 23 further comprising 100mM - 250mM sodium chloride.
25. A freeze-dried thrombin preparation comprising exogenous protein at a concentration of between 0.5g/l - 10g/l, 10mM - 30mM citrate and 100mM - 250mM sodium chloride.
26. A freeze-dried thrombin preparation according to any of claims 22 to 25 wherein the preparation has been heat-treated in order to inactivate any viral contaminants.
27. A freeze-dried thrombin preparation according to claim 26 wherein the heat-treated thrombin preparation has been dry

heat-treated at a temperature between 70°C to 100°C for up to 96 hours.

28. A freeze-dried thrombin preparation according to claim 26 wherein the heat-treated thrombin preparation has been heat-treated at approximately 80°C for around 72 hours.
29. A freeze-dried thrombin preparation according to any of claims 22 to 28 wherein the preparation is freeze-dried employing a two-stage freezing procedure; comprising a primary drying at a shelf temperature of -20°C to -30°C and a secondary drying at a shelf temperature of +15°C to +30°C.

1-2


Thrombin generation and specific activity  
in various batches of livestock

FIG. 1



2 - 2

Thrombin generation effects of calcium concentration in different feedstocks.

FIG. 2

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 96/00423

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12N9/74 A61K38/48

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 378 798 (BIOTEST PHARMA GMBH) 25 July 1990 cited in the application see page 3, line 1 - page 4, line 30 ---	1-4, 10-18
X	EP,A,0 528 701 (ASSOCIATION POUR L'ESSOR DE LA TRANSFUSION SANGUINE ) 24 February 1993 cited in the application see page 3, line 1 - line 10 ---	4,10-18
X	EP,A,0 541 507 (IMMUNO AK) 12 May 1993 see examples 1-4 --- -/-	4,10-18

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*A\* document member of the same patent family

Date of the actual completion of the international search

31 May 1996

Date of mailing of the international search report

27.06.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Fernandez y Branas, F

# INTERNATIONAL SEARCH REPORT

national Application No  
PCT/GB 96/00423

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SIGMA CHEMICAL CO.: "Biochemicalien organische verbindingen voor research en diagnostica" 1994 , SIGMA CHEMIE , BORNEM, BELGIE XP002004367 see page 982 - page 983 ---	19-29
A	EP,A,0 378 208 (THE GREEN CROSS CORPORATION) 18 July 1990 see example 3 ---	15,17
A	US,A,5 219 995 (HERRING S.W.) 15 June 1993 see examples 4,5 -----	1-29

# INTERNATIONAL SEARCH REPORT

national Application No  
PCT/GB 96/00423

PC17db 30/00423

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-378798	25-07-90	DE-A- 3843126	28-06-90
		DE-D- 58907303	28-04-94
		ES-T- 2051970	01-07-94
		US-A- 5143838	01-09-92
EP-A-528701	24-02-93	FR-A- 2679251	22-01-93
		CA-A- 2073734	19-01-93
		JP-A- 5186369	27-07-93
		US-A- 5304372	19-04-94
EP-A-541507	12-05-93	AT-B- 398079	26-09-94
		AT-A- 218391	15-01-94
		AU-B- 645715	20-01-94
		AU-B- 2736192	06-05-93
		CA-A- 2081703	05-05-93
		FI-A- 924975	05-05-93
		HR-A- 921171	31-08-95
		HU-A- 65390	28-06-94
		JP-A- 6046852	22-02-94
		PL-A- 296460	13-12-93
		SI-A- 9200299	30-06-94
EP-A-378208	18-07-90	DE-D- 69011136	08-09-94
		DE-T- 69011136	02-03-95
		ES-T- 2057191	16-10-94
		JP-A- 3218322	25-09-91
		US-A- 5151499	29-09-92
US-A-5219995	15-06-93	AU-B- 4677193	31-01-94
		CA-A- 2116691	20-01-94
		EP-A- 0607392	27-07-94
		JP-T- 6511018	08-12-94
		WO-A- 9401466	20-01-94